Akebia Therapeutics, Inc. (AKBA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Akebia Therapeutics, Inc. (AKBA) Healthcare & Pipeline Overview

Akebia Therapeutics, Inc. develops and commercializes therapeutics for kidney diseases, with a focus on anemia due to chronic kidney disease (CKD). The company's lead product candidate, vadadustat, is in Phase III development, positioning Akebia in the competitive biotechnology sector focused on renal care.

What Is the Investment Thesis for AKBA?

Akebia Therapeutics presents a focused investment opportunity within the renal disease therapeutics market. The primary value driver is the potential approval and commercial success of vadadustat for treating anemia in CKD patients. Positive Phase III trial results and subsequent regulatory approvals in key markets like the US and EU are critical catalysts. The company's existing product, Auryxia, provides a revenue stream while vadadustat progresses through development. Key risks include potential regulatory setbacks for vadadustat, competition from existing and emerging anemia treatments, and the company's ability to effectively commercialize vadadustat upon approval. Akebia's collaborations with Otsuka and Mitsubishi Tanabe Pharma are crucial for mitigating commercialization risks and expanding market access.

Based on FMP financials and quantitative analysis

AKBA Key Highlights

Market Cap of $247M reflects investor sentiment regarding the potential of vadadustat and Auryxia.

• Gross Margin of 81.0% indicates strong pricing power for Auryxia and potential for vadadustat.
• Free Cash Flow of $0.09 billion provides financial flexibility for ongoing clinical trials and commercialization efforts.
• P/E Ratio of -14.79 reflects the company's current lack of profitability due to ongoing R&D expenses.
• Beta of 0.40 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.

Who Are AKBA's Competitors?

AKBA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AKBA's Key Strengths?

Lead product candidate, vadadustat, in Phase III clinical development.

• Existing revenue stream from Auryxia.
• Strategic collaborations with Otsuka and Mitsubishi Tanabe Pharma.
• Experienced management team with expertise in renal disease therapeutics.

What Are AKBA's Weaknesses?

Reliance on the successful development and commercialization of vadadustat.

• Competition from established anemia treatments and emerging therapies.
• Dependence on collaboration partners for commercialization in certain territories.
• Negative Profit Margin indicates lack of profitability.

What Could Drive AKBA Stock Higher?

Potential regulatory approval of vadadustat in the United States, European Union, and Japan.

• Continued enrollment and data readout from ongoing clinical trials of vadadustat.
• Expansion of Auryxia sales and market share in existing markets.
• Potential announcement of new strategic collaborations or partnerships.

What Are the Key Risks for AKBA?

Financial-distress signal — its Altman Z-Score of -5.72 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-79.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory rejection of vadadustat by the FDA, EMA, or other regulatory agencies.
• Competition from existing anemia treatments and emerging therapies.
• Clinical trial failures or unexpected safety issues with vadadustat.
• Dependence on collaboration partners for commercialization success.
• Changes in reimbursement policies that could impact the pricing and market access of vadadustat and Auryxia.

What Are the Growth Opportunities for AKBA?

• Expansion of Vadadustat into New Markets: Akebia has the opportunity to expand the market reach of vadadustat beyond its current collaboration agreements. Securing regulatory approvals and establishing commercial partnerships in additional regions, such as Latin America and Southeast Asia, could significantly increase vadadustat's revenue potential. This expansion could occur within the next 3-5 years, contingent on successful clinical trials and regulatory reviews.
• Development of Next-Generation HIF-PH Inhibitors: Akebia's research and license agreement with Janssen Pharmaceutica NV provides access to a pipeline of novel HIF-PH inhibitors. Developing and commercializing next-generation compounds with improved efficacy, safety, or dosing profiles could provide a competitive advantage in the anemia treatment market. The timeline for this growth opportunity is longer-term, potentially 5-10 years, as it involves preclinical research, clinical trials, and regulatory approvals.
• Increased Adoption of Auryxia in Existing Markets: Akebia can focus on increasing the adoption of Auryxia for the treatment of hyperphosphatemia and iron deficiency anemia in CKD patients. This involves expanding the sales and marketing efforts to reach more nephrologists and patients. The market for hyperphosphatemia treatments is estimated to be significant, and increased market penetration could drive revenue growth. This growth opportunity can be realized in the near term, within the next 1-2 years, through targeted marketing campaigns and physician education.
• Strategic Acquisitions or Partnerships: Akebia could pursue strategic acquisitions or partnerships to expand its product portfolio and pipeline. This could involve acquiring companies with complementary technologies or therapies in the renal disease space. Such acquisitions could provide access to new markets, diversify revenue streams, and enhance Akebia's competitive position. The timing of this growth opportunity is uncertain, as it depends on the availability of suitable acquisition targets and the company's financial resources.
• Lifecycle Management of Vadadustat: Akebia can focus on lifecycle management strategies for vadadustat to extend its market exclusivity and maximize its revenue potential. This could involve developing new formulations, indications, or dosing regimens for vadadustat. For example, Akebia could explore the use of vadadustat in combination with other therapies or in different patient populations. These lifecycle management strategies could extend the commercial viability of vadadustat beyond its initial patent expiration.

What Threats Does AKBA Face?

• Regulatory setbacks for vadadustat.
• Competition from biosimilars and generic drugs.
• Changes in reimbursement policies.
• Product liability claims.

What Are AKBA's Competitive Advantages?

• Patent protection for vadadustat and Auryxia.
• Strategic collaborations with Otsuka and Mitsubishi Tanabe Pharma.
• Proprietary knowledge and expertise in HIF-PH inhibitor development.
• Established relationships with nephrologists and key opinion leaders.

What Does AKBA Do?

Akebia Therapeutics, Inc., founded in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with kidney diseases. The company's primary focus is on addressing anemia resulting from chronic kidney disease (CKD). Akebia's lead product candidate is vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Vadadustat is currently in Phase III clinical development for treating anemia in both dialysis-dependent (DD-CKD) and non-dialysis dependent (NDD-CKD) adult patients. The company also markets Auryxia (ferric citrate), a product indicated for controlling serum phosphorus levels in DD-CKD patients on dialysis and for the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia has established strategic collaboration agreements to expand the reach of vadadustat. These include partnerships with Otsuka Pharmaceutical Co. Ltd. for commercialization in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries, and with Mitsubishi Tanabe Pharma Corporation for development and commercialization in Japan and other Asian countries. Additionally, Akebia has a research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide.

What Products and Services Does AKBA Offer?

• Develop and commercialize therapeutics for patients with kidney diseases.
• Focus on treating anemia due to chronic kidney disease (CKD).
• Offer vadadustat, an oral therapy in Phase III development for anemia in CKD patients.
• Market Auryxia for controlling serum phosphorus levels in dialysis patients.
• Provide Auryxia for treating iron deficiency anemia in CKD patients not on dialysis.
• Collaborate with Otsuka Pharmaceutical for vadadustat commercialization in multiple regions.
• Partner with Mitsubishi Tanabe Pharma for vadadustat development in Japan and Asia.
• Engage in research and licensing agreements with Janssen Pharmaceutica for HIF-PH targeted compounds.

How Does AKBA Make Money?

• Develop and obtain regulatory approval for pharmaceutical products.
• Manufacture and market approved products, such as Auryxia.
• Generate revenue through product sales and licensing agreements.
• Collaborate with partners for commercialization in specific territories.

What Industry Does AKBA Operate In?

Akebia operates within the biotechnology industry, specifically targeting the renal disease therapeutics market. This market is driven by the increasing prevalence of chronic kidney disease (CKD) globally, fueled by factors such as diabetes and hypertension. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing treatments for anemia and other CKD-related complications. Akebia's vadadustat competes with existing erythropoiesis-stimulating agents (ESAs) and emerging HIF-PH inhibitors. The market is characterized by stringent regulatory requirements and the need for innovative therapies to improve patient outcomes.

Who Are AKBA's Key Customers?

• Dialysis-dependent chronic kidney disease (DD-CKD) patients.
• Non-dialysis dependent chronic kidney disease (NDD-CKD) patients.
• Adult patients with iron deficiency anemia and CKD.
• Nephrologists and other healthcare providers treating kidney disease patients.

Akebia Therapeutics, Inc. (AKBA) Valuation Context

Valued at $247M, AKBA is classified as a micro-cap stock. Relative to its peer group, AKBA's quantitative score of 18/100 is below the peer average of 74/100.

AKBA Revenue & Earnings Trend

In Q2 2026, AKBA generated $49.1M in top-line revenue, marking a sequential decrease of 8.2%. The company recorded a net loss of $8.9M, with diluted EPS of $-0.03. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, AKBA averaged $-0.03 in diluted EPS.

Company Profile

Akebia Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO John Butler. AKBA has traded publicly since 2014.

Return on equity for Akebia Therapeutics, Inc. stands at -79.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

Akebia Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.72 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Akebia Therapeutics, Inc. revenue of about $207.0M for fiscal 2026, with EPS near $-0.13. The estimate reflects 4 contributing analysts.

AKBA Financials

AKBA Latest News

AKBA Analyst Consensus

AKBA MoonshotScore

What Investors Ask About Akebia Therapeutics, Inc. (AKBA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources